LP-211
Cat. No.：YN320439
CAS No. ：1052147-86-0
| 产品名称: | LP-211 |
| CAS No.: | 1052147-86-0 |
| Chemical Name: | 4-[1,1′-biphenyl]-2-yl-N-[(4-cyanophenyl)methyl]-1-piperazinehexanamide |
| Synonyms: | 6-(4-Biphenyl-2-yl-piperazin-1-yl)-hexanoic acid 4-cyano-benzylamide;N-(4-Cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide;N-[(4-Cyanophenyl)methyl]-4-[1,1′-biphenyl]-2-yl-1-piperazinehexanamide;GS-9674;GS9674;PX-104Cilofexor 1052147-86-0;LP-211 |
| 分子量: | 466.62 |
| 分子式: | C₃₀H₃₄N₄O |
| SMILES: | O=C(NCC1=CC=C(C#N)C=C1)CCCCCN2CCN(C3=CC=CC=C3C4=CC=CC=C4)CC2 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | LP-211 是一种选择性的，可透过血脑屏障的5-HT7受体激动剂，Ki值为 0.58 nM，选择性高于 5-HT1A受体 (Ki，188 nM) 和 D2受体 (Ki，142 nM)。 |
| IC50和靶点: | [{name:"5-HT7 Receptor:0.58 nM (Ki)"},{name: "5-HT1A Receptor:188 nM (Ki)"},{name: "D2 Receptor:142 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Leopoldo, M., Lacivita, E., De Giorgio, P., et al.Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: Influence on lipophilicity and 5-HT7 receptor activity. Part IIIJ. Med. Chem.51(18),5813-5822(2008)
Lacivita, E., Podlewska, S., Speranza, L., et al.Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve in vitro microsomal stability: A case studyEur. J. Med. Chem.120,363-379(2016)
